Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease
| Autor: | Rocío Sedano Muñoz, Gonzalo Pizarro Jofré, Jaime Lubascher Correa, Rodrigo Quera Pino, Daniela Simian Marín |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Necrosis Tumor Necrosis Factor-alpha business.industry Treatment withdrawal Inflammatory Bowel Diseases medicine.disease Inflammatory bowel disease Infliximab Clinical Practice 03 medical and health sciences 0302 clinical medicine Withholding Treatment 030220 oncology & carcinogenesis Internal medicine medicine Adalimumab Humans 030211 gastroenterology & hepatology medicine.symptom business Anti tnf α therapy De-escalation medicine.drug |
| Zdroj: | Gastroenterología y Hepatología (English Edition). 42:133-140 |
| ISSN: | 2444-3824 |
| DOI: | 10.1016/j.gastre.2019.02.013 |
| Popis: | Anti-tumour necrosis factor α therapy in inflammatory bowel disease has been shown to be effective in clinical practice. After more than a decade using these therapies the question arises about whether there is an appropriate time to suspend these therapies, and how this should be done. This review aims to evaluate the current evidence on these topics concerning anti-tumour necrosis factor α therapies, and eventually identify conditions and subgroups of patients that could potentially be candidates for withdrawal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect